Participation in clinical trials is an individual, and important, decision. There are many advantages to participating in a trial, including care from medical teams experienced with the disease and the opportunity to try a new medication long before it is approved by the Food and Drug Administration to treat an indicated condition.
If you choose to participate in a clinical trial, you have the right to understand fully what is expected of you, what the trial will involve and the potential risks to your health. You also have the right to withdraw your consent to participate at any time. For more resources about trial participation and informed consent, please see the resources available from the U.S. Department of Health and Human Services.
Please note: Trials that are recruiting patients with eosinophil-associated disease and a search engine that can help match you to an enrolling trial appear below. Neither the list nor search engine results are considered exhaustive. The clinical trials listed here were verified as open and enrolling at the time the post was made, and are monitored periodically to ensure that the trial is still accepting participants. If a trial is no longer accepting patients, APFED may not be notified. If you find registration has closed for a trial that is still listed on this page, please notify mail@apfed.org.
Trials of Interest:
Eosinophilic Esophagitis
Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects with Eosinophilic Esophagitis
This trial is being conducted to determine the safety and effectiveness of an FDA approved drug called Zemaira in adults with eosinophilic esophagitis (EoE). Participation may last up to 32 weeks.
Participants will be asked to:
⦁ Take IV infusions of the study drug weekly for 8 weeks
⦁ Answer questions related to their symptoms and quality of life
⦁ Provide blood and urine samples
⦁ Complete two standard of care endoscopies during the study
You may qualify if you:
⦁ Are between the ages of 18 and 70
⦁ Are experiencing active EoE with symptoms
⦁ Willing to maintain current dietary regimen
For more information, please call Rosa Lykins 513-517-1102 or email Rosa.Lykins@cchmc.org
Learn more about CEGIR and its work at rdcrn.org/cegir
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
The CROSSING study for adults and adolescents with EoE
The CROSSING clinical research study is evaluating the safety and efficacy of tezepelumab for the treatment of Eosinophilic Esophagitis (EoE) in patients between 12 and 80 years of age.
A Study to Evaluate the efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Ages: 12-75 years old
Study Reference: NCT04753697 and CC-93538-EE-001
Study Type: Interventional
Location: Multiple locations in U.S. Learn More
OMEGA-A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG), Gastroenteritis (EGE) and Colitis (EC)
Ages: 3-65
Study Reference: NCT02523118
Study Type: Observational
Location: Multiple locations in U.S. Learn more Download the flyer
Phase 2 Study of Esophageal String Test in Eosinophilic Esophagitis
Ages: 7-65
Study Reference: NCT02008903
Study type: Observational
Location: Children’s Hospital Colorado (Aurora, CO); Lurie Children’s Hospital (Chicago, IL); Northwestern University (Chicago, IL) Learn more
Fibrostenotic Eosinophilic Esophagitis: Endoscopic, Histologic and Molecular Characterization and Evaluation of Clinical Assessment Tools
Ages: 5-80
Study Reference: NCT02453126
Study type: Observational
Location: Mayo Clinic, Rochester, MI Learn more
Protocol for Food Antigen Staining in Esophageal Mucosa in Patients With Eosinophilic Esophagitis
Ages: 18-80
Study Reference: NCT02434705
Study type: Interventional
Location: Mayo Clinic, Rochester, MI Learn more
A Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Gastritis with or without Eosinophilic Duodenitis
Ages of participants: Adults and adolescents
Type of Study: Interventional
Location: US, Canada, Japan, Australia, Italy, Poland, and France
Learn more: Welcome to Engage Clinical Study
Clinicaltrials.gov identifier: NCT05831176
PilOt Assessment to Find Evidence of Gastric Motility Abnormalities in Eosinophilic Gastric Disorders (OAT-FEED)
Ages: 18-59
Study Type: Observational
Location: Multiple locations in U.S. Learn More
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (ANTI-IL4RA) in Subjects with Eosinophilic Gastritis
OMEGA-A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG), Gastroenteritis (EGE) and Colitis (EC)
Ages: 3-65
Study Reference:NCT02523118
Study Type: Observational
Location: Multiple locations in U.S. Learn more
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Ages: any age
Study Reference: NCT00091871
Study type: Observational
Location: Bethesda, MD Learn more
Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients With Myeloproliferative and/or Steroid-Refractory Hypereosinophilic Syndrome
Ages: 2+
Study Reference: NCT00044304
Study type: Interventional
Location: Bethesda, MD Learn more
Eosinophilic Fasciitis
Coordination of Rare Diseases at Sanford
Ages: not specified
Study Reference: NCT01793168
Study type: Observational
Location: Sioux Falls, SD Learn more
Eosinophilic Asthma
A 52-week study to assess the safety and efficacy of Dexpramipexole, an oral eosinophil lowering therapy, in adolescents and adults with Severe Eosinophilic Asthma (GINA steps 4 and 5).
A 52-week study to assess the safety and efficacy of Dexpramipexole, an oral eosinophil lowering therapy, in adolescents and adults with Severe Eosinophilic Asthma (GINA steps 4 and 5).
A 24-week study to assess the safety and efficacy of Dexpramipexole, an oral eosinophil lowering therapy, in adolescents and adults with moderate to severe Eosinophilic Asthma (GINA steps 3, 4, and 5).
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok